08:00 , Nov 10, 2014 |  BC Week In Review  |  Clinical News

AVI-7100: Phase I data

Data from 40 healthy volunteers in the single ascending-dose portion of a double-blind, placebo-controlled, U.S. Phase I trial showed that IV AVI-7100 was well tolerated at doses of up to 8 mg/kg. No serious or...
07:00 , Jun 27, 2011 |  BC Week In Review  |  Clinical News

AVI-7100: Phase I started

AVI BioPharma began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate single ascending-doses of IV AVI-7100 in about 48 healthy adult volunteers. AVI BioPharma Inc. (NASDAQ:AVII), Bothell, Wash.   Product: AVI-7100   Business: Infectious   Molecular...
07:00 , Aug 30, 2010 |  BC Week In Review  |  Clinical News

AVI BioPharma preclinical data

In ferrets infected with pandemic H1N1 influenza virus, intraperitoneal 10 mg/kg AVI-7100 reduced combined daily average viral titer through peak viral load (days 1-3) by up to 3.9 log10 copies/mL, which was significant vs. each...